Gheita T A, Abdel Rehim D M, Kenawy S A, Gheita H A
Acta Reumatol Port. 2015 Apr-Jun;40(2):145-9.
To assess the serum level of matrix metalloproteinase-3 (MMP-3) in systemic lupus erythematosus (SLE) patients and correlate it with clinical manifestations, laboratory findings, disease activity and damage.
Forty-two female SLE patients were included in the present study. Full history taking, thorough examination and investigations were performed. Disease activity was assessed using the SLE disease activity index (SLEDAI). Furthermore, Systemic Lupus International Collaborating Clinics /American College of Rheumatology damage index (SLICC/ACR DI) was also assessed. Renal biopsy was done in those with lupus nephritis. Thirty age and sex matched subjects were included as control. Serum MMP-3 was measured by ELISA.
The mean serum MMP-3 level in SLE patients was significantly higher (80.9±45.8 ng/ml) than in the control (10.01±2.6 ng/ml) (p <0.0001). The level in patients with arthritis, nephritis or hematologic disorders were significantly higher than in those without (p<0.0001, p=0.02 and p=0.04 respectively). The MMP-3 was significantly different among the subclasses of renal biopsy (p=0.01) being higher in those with class IV (137.5±45.6 ng/ml). It significantly correlated with the SLEDAI, SLICC, white blood cells and platelet counts (r=0.37, p=0.02; r=0.36, p=0.02; r=0.32, p 0.04 and r=0.38, p=0.01 respectively). On linear regression analysis with age, disease duration and body mass index as independent factors, the SLEDAI and SLICC were not significant predictors.
Serum MMP-3 was found to be high in SLE patients and associated with arthritis, nephritis and hematological manifestations. Matrix metalloproteinase-3 correlated with disease activity and damage making it a possible biomarker and its measure of considerable interest related to the potential therapeutic responses and disease outcome.
评估系统性红斑狼疮（SLE）患者血清基质金属蛋白酶-3（MMP-3）水平，并将其与临床表现、实验室检查结果、疾病活动度及损伤情况相关联。
本研究纳入42例女性SLE患者。进行了全面的病史采集、详细检查及各项检查。采用SLE疾病活动指数（SLEDAI）评估疾病活动度。此外，还评估了系统性红斑狼疮国际协作临床中心/美国风湿病学会损伤指数（SLICC/ACR DI）。对狼疮性肾炎患者进行了肾活检。纳入30例年龄和性别匹配的受试者作为对照。采用酶联免疫吸附测定法（ELISA）检测血清MMP-3。
SLE患者血清MMP-3平均水平（80.9±45.8 ng/ml）显著高于对照组（10.01±2.6 ng/ml）（p<0.0001）。患有关节炎、肾炎或血液系统疾病的患者其MMP-3水平显著高于未患这些疾病的患者（分别为p<0.0001、p=0.02和p=0.04）。肾活检各亚类之间MMP-3水平有显著差异（p=0.01），IV级患者的MMP-3水平更高（137.5±45.6 ng/ml）。它与SLEDAI、SLICC、白细胞及血小板计数显著相关（r分别为0.37，p=0.02；r=0.36，p=0.02；r=0.32，p=0.04；r=0.38，p=0.01）。以年龄、病程和体重指数作为独立因素进行线性回归分析时，SLEDAI和SLICC并非显著的预测指标。
发现SLE患者血清MMP-3水平升高，且与关节炎、肾炎及血液系统表现相关。基质金属蛋白酶-3与疾病活动度及损伤相关，使其成为一种可能的生物标志物，其检测对于潜在的治疗反应和疾病转归具有重要意义。
